INVESTMENT THESIS
Breadth with advantage. Discipline with optionality.
A generational investment theme driven by structural system pressure.
We believe healthtech is the most compelling venture capital opportunity of this decade. Not because it's trendy, but because the structural forces driving it are irreversible.
STRUCTURAL OPPORTUNITY
The forces driving healthtech are irreversible
Healthcare systems globally are at breaking point. Ageing populations, chronic disease burden (90% of all deaths in Australia), and workforce shortages (84% healthcare worker burnout) are creating unsustainable cost pressures. Technology is the only lever that can bend the cost curve.
Australia is uniquely positioned. The healthtech ecosystem has grown 76% since 2019, with a 52% CAGR in company formation and 44% female founder participation, well above the 27% broader ecosystem average. A sophisticated healthcare system and world-class research institutions create an asymmetric opportunity for specialist early-stage capital.
Sources: ANDHealth Rising Giant Report, 2024; AIHW
Further Reading
For a deeper look at why the traditional healthcare model is under pressure and what Medicine 3.0 means for investors, read our analysis.
Read: The Rise of Medicine 3.0 →HEALTH VALUE CHAIN
Broad across the health value chain, weighted to where it matters most
We invest across the full health value chain. We deliberately weight toward prevention and early detection as strategic entry points, where regulatory friction is lower and validation faster, while maintaining a broad mandate across diagnostics, care delivery, and regulated therapeutics.
Prevention & Wellness
Intervening before disease onset
Early Detection
Diagnostics and screening
Treatment Optimisation
Improving clinical outcomes
Care Delivery
Workflow and infrastructure
Recovery & Management
Chronic disease and rehabilitation
Highlighted areas reflect our strategic weighting as entry points. Downstream innovation remains central to the mandate.
AI AS ENABLER
AI is not the thesis. It is a meaningful enabler of capital efficiency.
We don't invest in "AI companies." We invest in health companies where AI creates a compounding, defensible advantage, enabling disciplined experimentation while preserving optionality.
The distinction matters. AI should compress the cost of iteration, accelerate clinical validation, and create capital-efficient pathways to product-market fit, not serve as a wrapper for generic technology.
Clinical Decision Support
AI systems that augment clinician decision-making with real-time data synthesis and pattern recognition.
Predictive Analytics
Models that identify at-risk populations and predict disease progression before clinical presentation.
Operational Intelligence
AI applied to healthcare logistics, resource allocation, and administrative burden reduction.
Drug Discovery & Development
Machine learning accelerating target identification, compound screening, and clinical trial design.
OUR STRUCTURAL EDGE
Why Dreamoro wins in this market
Specialist focus creates advantages that generalist funds cannot replicate. As highlighted by Cut Through Venture's State of Australian Startup Funding 2025, sector-focused investing, including HealthTech, is a growing trend among Australia's most active investors.
Proprietary Deal Flow
Our ecosystem collaborations with LX Health, UNSW Founders, and Swinburne give us access to companies before they hit the market.
Operator Judgement
Every investment decision is informed by operational experience. We've built, scaled, and exited healthtech companies.
Studio Leverage
Portfolio companies access Dreamoro Studio capability at cost, including product engineering, UX, and GTM support.
Specialist LP Base
Our LPs are healthcare operators, clinicians, and industry leaders who actively support portfolio companies.
FOR LIMITED PARTNERS
A compelling case for specialist allocation
HealthTech is the fastest-growing venture category globally. Specialist funds consistently outperform generalist funds in emerging sectors.
Structural Theme
HealthTech is driven by irreversible demographic and fiscal pressures, not cyclical trends.
Specialist Access
Our ecosystem collaborations provide deal flow that generalist funds cannot access.
Capital Efficiency
Australian healthtech companies raise less, operate leaner, and reach milestones faster.
THE BOTTOM LINE
HealthTech is not a niche. It's a structural transformation of a $10 trillion industry.
Source: WHO, Global Health Expenditure Database
The founders solving these problems need specialist capital, deep domain networks, and operator support. That's what Dreamoro was built to provide.